ペムブロリズマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ペムブロリズマブ" in Japanese language version.

refsWebsite

Global rank Japanese rank

6nih.gov

4^th place

24^th place

5doi.org

2^nd place

6^th place

2msd.co.jp

low place

1nytimes.com

7^th place

63^rd place

1ynetnews.com

1,870^th place

4,702^nd place

1cancernetwork.com

low place

1cancerresearchuk.org

8,489^th place

low place

1mededge.jp

low place

1sciencemag.org

857^th place

1,005^th place

1nejm.org

2,374^th place

2,486^th place

1upenn.edu

702^nd place

2,232^nd place

1asco.org

low place

asco.org

meetinglibrary.asco.org

Julie R. Brahmer, Edward S. Kim, Jin Zhang, et al.. “KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1).”. Abstracts of 2015 ASCO Annual Meeting.

cancernetwork.com

“FDA Approves Anti-PD-1 Drug for Advanced Melanoma”. cancernetwork.com. 2015年6月14日閲覧。^{[リンク切れ]}

cancerresearchuk.org

“New immunotherapy drug ‘fast-tracked’ for melanoma patients”. Cancer Research UK (2015年3月11日). 2015年6月14日閲覧。

doi.org

Hamid, O; Robert, C; Daud, A; Hodi, F. S.; Hwu, W. J.; Kefford, R; Wolchok, J. D.; Hersey, P et al. (2013). “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. New England Journal of Medicine 369 (2): 134-44. doi:10.1056/NEJMoa1305133. PMID 23724846.
Francisco LM, Sage PT, Sharpe AH (Jul 2010). “The PD-1 pathway in tolerance and autoimmunity”. Immunological Reviews 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
Pardoll, DM (Mar 22, 2012). “The blockade of immune checkpoints in cancer immunotherapy.”. Nature reviews. Cancer 12 (4): 252–64. doi:10.1038/nrc3239. PMID 22437870.
Sharma, Pamanee; Allison, James P. (April 3, 2015). “The future of immune checkpoint therapy”. Science. doi:10.1126/science.aaa8172 June 2015閲覧。.
Garon EB, Rizvi NA, Hui R, et al. (2015-05-21). “Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer.”. N Engl J Med. 372 (21): 2018-28. doi:10.1056/NEJMoa1501824. PMID 25891174.

mededge.jp

“抗がん剤に「迅速承認」の動き、悪性黒色腫のための免疫療法薬ペンブロリズマブ、英国”. Medエッジ (2015年3月29日). 2015年6月14日閲覧。^{[リンク切れ]}

msd.co.jp

“Merck & Co., Inc., Kenilworth, N.J., U.S.A.の抗PD-1抗体KEYTRUDA（ペムブロリズマブ）プラチナ製剤ベースの化学療法施行中または施行後に進行したPD-L1陽性転移性非小細胞肺がんの治療薬としてFDAが承認”. MSD (2015年10月9日). 2015年10月13日閲覧。
“抗PD-1抗体/抗悪性腫瘍剤「キイトルーダ」製造販売承認を取得”. MSD (2016年9月28日). 2016年11月22日閲覧。

nejm.org

Garon EB, Rizvi NA, Hui R, et al. (2015-05-21). “Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer.”. N Engl J Med. 372 (21): 2018-28. doi:10.1056/NEJMoa1501824. PMID 25891174.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hamid, O; Robert, C; Daud, A; Hodi, F. S.; Hwu, W. J.; Kefford, R; Wolchok, J. D.; Hersey, P et al. (2013). “Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma”. New England Journal of Medicine 369 (2): 134-44. doi:10.1056/NEJMoa1305133. PMID 23724846.
Francisco LM, Sage PT, Sharpe AH (Jul 2010). “The PD-1 pathway in tolerance and autoimmunity”. Immunological Reviews 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
Pardoll, DM (Mar 22, 2012). “The blockade of immune checkpoints in cancer immunotherapy.”. Nature reviews. Cancer 12 (4): 252–64. doi:10.1038/nrc3239. PMID 22437870.
Garon EB, Rizvi NA, Hui R, et al. (2015-05-21). “Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer.”. N Engl J Med. 372 (21): 2018-28. doi:10.1056/NEJMoa1501824. PMID 25891174.

ncbi.nlm.nih.gov

Francisco LM, Sage PT, Sharpe AH (Jul 2010). “The PD-1 pathway in tolerance and autoimmunity”. Immunological Reviews 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.

pmc.ncbi.nlm.nih.gov

Francisco LM, Sage PT, Sharpe AH (Jul 2010). “The PD-1 pathway in tolerance and autoimmunity”. Immunological Reviews 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.

nytimes.com

Pollack, Andrew (May 29, 2015). “New Class of Drugs Shows More Promise in Treating Cancer”. New York Times May 30, 2015閲覧。

sciencemag.org

Sharma, Pamanee; Allison, James P. (April 3, 2015). “The future of immune checkpoint therapy”. Science. doi:10.1126/science.aaa8172 June 2015閲覧。.

upenn.edu

Press release, "Penn Medicine's New Immunotherapy Study Will Pit PD-1 Inhibitor Against Advanced Lung Cancer", February 4, 2015.

ynetnews.com

Duek, Nechama (June 9, 2014). “Israeli-American team unveils revolutionary drug in fight against skin cancer”. ynetnews.com June 2015閲覧。